330 related articles for article (PubMed ID: 25496192)
1. Gene-deleted live-attenuated Trypanosoma cruzi parasites as vaccines to protect against Chagas disease.
Sánchez-Valdéz FJ; Pérez Brandán C; Ferreira A; Basombrío MÁ
Expert Rev Vaccines; 2015 May; 14(5):681-97. PubMed ID: 25496192
[TBL] [Abstract][Full Text] [Related]
2. Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge.
Perez Brandan C; Padilla AM; Xu D; Tarleton RL; Basombrio MA
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1418. PubMed ID: 22180798
[TBL] [Abstract][Full Text] [Related]
3. Genetically attenuated Trypanosoma cruzi parasites as a potential vaccination tool.
Pérez Brandan C; Basombrío MÁ
Bioengineered; 2012; 3(4):242-6. PubMed ID: 22705838
[TBL] [Abstract][Full Text] [Related]
4. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
[TBL] [Abstract][Full Text] [Related]
5. Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against
Cerny N; Bivona AE; Sanchez Alberti A; Trinitario SN; Morales C; Cardoso Landaburu A; Cazorla SI; Malchiodi EL
Front Immunol; 2020; 11():565142. PubMed ID: 33162979
[TBL] [Abstract][Full Text] [Related]
6. Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge.
Collins MH; Craft JM; Bustamante JM; Tarleton RL
Infect Immun; 2011 Aug; 79(8):3397-406. PubMed ID: 21628516
[TBL] [Abstract][Full Text] [Related]
7. Induction of Effective Immunity against Trypanosoma cruzi.
Williams T; Guerrero-Ros I; Ma Y; Matos Dos Santos F; Scherer PE; Gordillo R; Horta A; Macian F; Weiss LM; Huang H
Infect Immun; 2020 Mar; 88(4):. PubMed ID: 31907197
[TBL] [Abstract][Full Text] [Related]
8. Trypanosoma cruzi: effect of immunization on the risk of vector-delivered infection in guinea pigs.
Basombrío MA; Nasser JR; Segura MA; Gomez LE
J Parasitol; 1997 Dec; 83(6):1059-62. PubMed ID: 9406779
[TBL] [Abstract][Full Text] [Related]
9. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction?
Basso B; Marini V
Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810
[TBL] [Abstract][Full Text] [Related]
10. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2.
Duan X; Yonemitsu Y; Chou B; Yoshida K; Tanaka S; Hasegawa M; Tetsutani K; Ishida H; Himeno K; Hisaeda H
Vaccine; 2009 Oct; 27(44):6154-9. PubMed ID: 19712768
[TBL] [Abstract][Full Text] [Related]
11. Prospects of defined proteins for vaccine development.
Frasch AC; Sánchez DO; Cazzulo JJ
Mem Inst Oswaldo Cruz; 1990; 85(4):523-9. PubMed ID: 2152211
[No Abstract] [Full Text] [Related]
12.
Trevisan RO; Santos MM; Desidério CS; Alves LG; de Jesus Sousa T; de Castro Oliveira L; Jaiswal AK; Tiwari S; Bovi WG; de Oliveira-Silva M; Costa-Madeira JC; Castellano LRC; Silva MV; Azevedo V; Rodrigues Junior V; Oliveira CJF; de Castro Soares S
Dis Markers; 2020; 2020():9130719. PubMed ID: 33488847
[TBL] [Abstract][Full Text] [Related]
13. Advances and challenges towards a vaccine against Chagas disease.
Quijano-Hernandez I; Dumonteil E
Hum Vaccin; 2011 Nov; 7(11):1184-91. PubMed ID: 22048121
[TBL] [Abstract][Full Text] [Related]
14. Therapeutical effects of vaccine from Trypanosoma cruzi amastigote surface protein 2 by simultaneous inoculation with live parasites.
Ribeiro FAP; Pontes C; Machado AMV; Bruna-Romero O; Quintana HT; De Oliveira F; De Vasconcelos JRC; Ribeiro DA
J Cell Biochem; 2019 Mar; 120(3):3373-3383. PubMed ID: 30246366
[TBL] [Abstract][Full Text] [Related]
15. Experimental Vaccines against Chagas Disease: A Journey through History.
Rodríguez-Morales O; Monteón-Padilla V; Carrillo-Sánchez SC; Rios-Castro M; Martínez-Cruz M; Carabarin-Lima A; Arce-Fonseca M
J Immunol Res; 2015; 2015():489758. PubMed ID: 26090490
[TBL] [Abstract][Full Text] [Related]
16. From genome screening to creation of vaccine against Trypanosoma cruzi by use of immunoinformatics.
Teh-Poot C; Tzec-Arjona E; Martínez-Vega P; Ramirez-Sierra MJ; Rosado-Vallado M; Dumonteil E
J Infect Dis; 2015 Jan; 211(2):258-66. PubMed ID: 25070943
[TBL] [Abstract][Full Text] [Related]
17. A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors.
Farrow AL; Peng BJ; Gu L; Krendelchtchikov A; Matthews QL
Viruses; 2016 Mar; 8(3):78. PubMed ID: 26978385
[TBL] [Abstract][Full Text] [Related]
18. Neglected tropical diseases, bioinformatics, and vaccines.
Rodrigues MM; Ersching J
J Infect Dis; 2015 Jan; 211(2):175-7. PubMed ID: 25070940
[No Abstract] [Full Text] [Related]
19. Trypanosoma cruzi infection from the view of CD8+ T cell immunity--an infection model for developing T cell vaccine.
Miyahira Y
Parasitol Int; 2008 Mar; 57(1):38-48. PubMed ID: 17728174
[TBL] [Abstract][Full Text] [Related]
20. Chronic Chagas disease: can prophylaxis and therapeutic vaccines crack this 'hard nut'?
Bontempi I; Vicco MH; Bayry J
Immunotherapy; 2016 Feb; 8(2):99-101. PubMed ID: 26787323
[No Abstract] [Full Text] [Related]
[Next] [New Search]
